PCS
SYRE icon

Personal CFO Solutions’s Spyre Therapeutics SYRE Stock Holding History

Personal CFO Solutions’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-436
Closed -$87K – 514
2021
Q3 		$87K Sell
436
-20
-4% -$3.5K 0.02% 439
2021
Q2 		$79K Hold
456
– – 0.02% 428
2021
Q1 		$90K Hold
456
– – 0.02% 393
2020
Q4 		$90K Buy
+456
New +$94.5K 0.02% 361

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Personal CFO Solutions's SYRE Position: Q4 2021 in Review

Personal CFO Solutions sold out of Spyre Therapeutics (SYRE) in Q4 2021, closing a stake of 436 shares — an estimated $87K sold.

Personal CFO Solutions first reported a position in SYRE in Q4 2020 and held it in 4 quarters. The position peaked at $90K in Q1 2021. 85 funds tracked by Wall St. Rank hold SYRE as of Q4 2021.

  • Personal CFO Solutions reported no remaining Spyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Personal CFO Solutions sold 436 Spyre Therapeutics shares in Q4 2021, an estimated $87K.
  • Personal CFO Solutions first reported a position in Spyre Therapeutics in Q4 2020 and held it in 4 quarters.
  • Personal CFO Solutions's Spyre Therapeutics position peaked at $90K in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2021.

Based on Personal CFO Solutions's 13F filing for Q4 2021, filed 11 Feb 2022.